Pierre Heimendinger PharmD

Pierre Heimendinger is a Vice President at Sangamo Therapeutics France. Pierre has over 29 years of experience in the pharmaceutical industry and specifically in the field of biotechnology, immunotherapy, vaccines, plasma-derived medicinal products, and viral vectors. Pierre gained his experience in manufacturing processes of development and analytical methods of control through numerous positions he has held in research and development, industrialization processes, production, and quality control for products for Phase 1, 2, and 3 clinical trials and for commercial products on the market. He has improved the robustness of products as well as control strategies as well as enrolled new drugs in clinical trials as guidelines alter. He has achieved this by implementing quality by design and process analytical technology through the development of regulatory proceedings. Before joining TxCell in 2015, Pierre held a senior director position at Transgene SA where he led the pharmaceutical development team and was responsible for the development of new processes, analytical methods, and technology transfer immunotherapy treatments using viral vectors. He started his career at Sanofi Pasteur where he held several positions in R&D and production, then at Mérieux and Octapharma. Pierre has a doctor of pharmacy degree complemented by a postgraduate in cellular and genetic toxicology from the University of Paris VII.